Clinical Trial: IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer

U.S., Jan. 31 -- ClinicalTrials.gov registry received information related to the study (NCT07377643) titled 'IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer' on Jan. 15.

Brief Summary: This is a randomized, multicenter, open-label, phase 3 study evaluating the efficacy, safety, and tolerability of IBI354 combined with or without pertuzumab vs. THP as first-line treatment for HER2-positive unresectable, locally advanced or metastatic breast cancer.

Study Start Date: Feb. 28

Study Type: INTERVENTIONAL

Condition: HER2-positive Breast Cancer

Intervention: DRUG: Trastuzumab

IV infusion

DRUG: IBI354

IV infusion

DRUG: Docetaxel

IV infusion

DRUG: Pertuzumab

IV infus...